Tylenol Multidistrict Litigation Moves Forward with Status Conference
A status conference was recently held to discuss various issues related to the Tylenol multidistrict litigation (MDL) No. 2436. On December 17, 2013, the parties presented their arguments with regards to a pending Motion for Protective Order, which had been filed by the defendants, Johnson & Johnson. The defendants filed the motion in an attempt to avoid disclosing certain information, such as data on Tylenol recalls and government investigations. The defendants argued that disclosing such information would unfairly prejudice the jury.
Throughout the pretrial proceedings of the MDL, both parties may file additional motions. Arguing motions and moving forward with the many other aspects of the discovery process can make the lawsuits take longer to resolve. Although the purpose of an MDL is to streamline the litigation process, it can still take months or even years before jury awards or settlements are reached.
Following a jury award or settlement, a plaintiff may still need to wait a long time before receiving payments. During this time, some plaintiffs may opt for Tylenol lawsuit funding to stay afloat while awaiting payments.
Tylenol lawsuit loans are loans in name only; in fact, they are cash advances based on the anticipated jury award or settlement.
Discovery expected to continue through 2014
During the recent status conference, Johnson & Johnson also discussed matters pertaining to the state litigation proceeding in New Jersey. All parties are currently undergoing pretrial discovery, which is expected to continue well into 2014. Early in 2014, the parties are expected to provide Judge Stengel, who is presiding over the MDL, with new information regarding depositions. No dates have been announced yet for the anticipated bellwether trials, which will be the first group of cases in the MDL to go to trial. It is expected that sometime in 2014, the Judge will issue an order with regards to the selection of the bellwether cases.
Plaintiffs share similar complaints
In any MDL, all of the plaintiffs involved share similar complaints and statements of fact. In the case of the Tylenol MDL, the plaintiffs allege that the popular pain reliever caused liver damage. According to the FDA, acetaminophen, which is the active ingredient in Tylenol, causes more than 450 deaths each year. Over 50,000 emergency room visits and 25,000 hospitalizations annually have been attributed to acetaminophen.
More than 100 product liability lawsuits are currently joined to the MDL, and more could continue to be centralized there. Although it is highly likely that the plaintiffs will receive compensation for their injuries, emotional trauma, and pain and suffering, they may struggle to pay their bills in the meantime.
Tylenol lawsuit funding eases financial hardships
Plaintiffs who are awaiting a jury award or settlement may have trouble paying for prohibitively expensive medical care, ongoing medical care needs, pharmaceutical fees, and other expenses related to their injuries, as well as their day-to-day bills. If they apply for Tylenol lawsuit funding, they’ll receive a cash advance toward their settlement or jury award, which will help them live comfortably as the litigation process moves forward.
A lawsuit loan from LawStreet Capital is offered at absolutely no risk to the plaintiff. LawStreet Capital is a direct lender, which means there are never any hidden fees nor is there any risk because it isn’t like a traditional bank loan. Should you lose your case, you’ll owe nothing. You can receive approval within 24 hours, with a lump sum payment shortly thereafter. If you have any questions or wish to apply, call 1.866.FUND.662 to speak with a friendly representative.
